Hostname: page-component-74656f9884-npj9w Total loading time: 0 Render date: 2026-11-08T22:32:42.366Z Has data issue: false hasContentIssue false

A framework and road map for rapid start-up and completion of a COVID-19 vaccine trial: A single clinical trial site experience

Published online by Cambridge University Press:  12 January 2022

Carlos Rojas*
Affiliation:
Altman Clinical & Translational Research Institute, University of California San Diego, San Diego, California, USA
Stephen A. Spector
Affiliation:
Division of Infectious Diseases, Mother-Child-Adolescent HIV Program, University of California San Diego and Rady Children’s Hospital, San Diego, California, USA
Bernadette Cale
Affiliation:
Altman Clinical & Translational Research Institute, University of California San Diego, San Diego, California, USA
Megan Loughran
Affiliation:
Mother-Child-Adolescent HIV Program, University of California San Diego, San Diego, California, USA
Leander Lazaro
Affiliation:
Altman Clinical & Translational Research Institute, University of California San Diego, San Diego, California, USA
Eric Mah
Affiliation:
Altman Clinical & Translational Research Institute, University of California San Diego, San Diego, California, USA
Gary S. Firestein
Affiliation:
Department of Medicine, Altman Clinical & Translational Research Institute, University of California San Diego, San Diego, California, USA
Kathryn A. Gold
Affiliation:
Division of Hematology and Oncology, Altman Clinical & Translational Research Institute, University of California San Diego, San Diego, California, USA
Mark Wallace
Affiliation:
Division of Pain Medicine, Department of Anesthesiology, Altman Clinical & Translational Research Institute, University of California San Diego, San Diego, California, USA
*
Address for correspondence: C. Rojas, Altman Clinical & Translational Research Institute, University of California San Diego, San Diego, California, USA. Email: carlosrojas@health.ucsd.edu
Rights & Permissions [Opens in a new window]

Abstract

The COVID-19 global pandemic required the rapid development of vaccines with a quick start up of phase 1–3 studies with large enrollment targets. The University of California San Diego was identified as a site for the phase 3 trial of the mRNA-1273-SARS-CoV-2 vaccine. There were many challenges with scaling up a large-scale clinical trial in such a short time. This report describes the processes and procedures that were implemented to successfully complete the enrollment target in under 10 weeks. This required the team to identify existing tools that could rapidly be accessed to develop a database, scheduling system, effective communication, document management, staff time tracking/efficiency, subject scheduling/tracking, project management, and accrual/study performance. The outcome of these efforts resulted in rapid enrollment and study completion in a short time. The lessons learned from this experience can be used by other clinical trial sites faced with similar challenges.

Information

Type
Translational Science Case Study
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of The Association for Clinical and Translational Science
Figure 0

Fig. 1. Two-pronged screening strategy to optimize coordinator time.

Figure 1

Fig. 2. Process flow to aid teams with scheduling.

Figure 2

Fig. 3. Actual enrollment for site by week; declining as participants return for second visits.

Figure 3

Fig. 4. Actual demographics data for accruals by week.

Supplementary material: File

Rojas et al. supplementary material

Rojas et al. supplementary material

Download Rojas et al. supplementary material(File)
File 481.7 KB